Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction.

Karolina Szummer; Jonas Oldgren; Lars Lindhagen; Juan Jesus Carrero; Marie Evans; Jonas Spaak; Robert Edfors; Stefan H Jacobson; Pontus Andell; Lars Wallentin; Tomas Jernberg

doi:10.1001/jama.2015.517

Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction.

Karolina Szummer, Jonas Oldgren, Lars Lindhagen, Juan Jesus Carrero, Marie Evans, Jonas Spaak, Robert Edfors, Stefan H Jacobson, Pontus Andell, Lars Wallentin, Tomas Jernberg

Cardiology

Research output: Contribution to journal › Article › peer-review

Abstract

Fondaparinux was associated with reduced major bleeding events and improved survival compared with low-molecular-weight heparin (LMWH) in a large randomized clinical trial involving patients with non-ST-segment elevation myocardial infarction (NSTEMI). Large-scale experience of the use of fondaparinux vs LMWH in a nontrial setting is lacking.

Original language	English
Pages (from-to)	707-716
Journal	JAMA: The Journal of the American Medical Association
Volume	313
Issue number	7
DOIs	https://doi.org/10.1001/jama.2015.517
Publication status	Published - 2015

Subject classification (UKÄ)

Cardiac and Cardiovascular Systems

Access to Document

10.1001/jama.2015.517

http://www.ncbi.nlm.nih.gov/pubmed/25688782?dopt=Abstract

Cite this

Szummer, K., Oldgren, J., Lindhagen, L., Carrero, J. J., Evans, M., Spaak, J., Edfors, R., Jacobson, S. H., Andell, P., Wallentin, L., & Jernberg, T. (2015). Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction. JAMA: The Journal of the American Medical Association, 313(7), 707-716. https://doi.org/10.1001/jama.2015.517

@article{de61832b00f74a829fc3e6a71a320293,

title = "Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction.",

abstract = "Fondaparinux was associated with reduced major bleeding events and improved survival compared with low-molecular-weight heparin (LMWH) in a large randomized clinical trial involving patients with non-ST-segment elevation myocardial infarction (NSTEMI). Large-scale experience of the use of fondaparinux vs LMWH in a nontrial setting is lacking.",

author = "Karolina Szummer and Jonas Oldgren and Lars Lindhagen and Carrero, {Juan Jesus} and Marie Evans and Jonas Spaak and Robert Edfors and Jacobson, {Stefan H} and Pontus Andell and Lars Wallentin and Tomas Jernberg",

year = "2015",

doi = "10.1001/jama.2015.517",

language = "English",

volume = "313",

pages = "707--716",

journal = "JAMA: The Journal of the American Medical Association",

issn = "1538-3598",

publisher = "American Medical Association",

number = "7",

}

Szummer, K, Oldgren, J, Lindhagen, L, Carrero, JJ, Evans, M, Spaak, J, Edfors, R, Jacobson, SH, Andell, P, Wallentin, L & Jernberg, T 2015, 'Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction.', JAMA: The Journal of the American Medical Association, vol. 313, no. 7, pp. 707-716. https://doi.org/10.1001/jama.2015.517

Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction. / Szummer, Karolina; Oldgren, Jonas; Lindhagen, Lars et al.
In: JAMA: The Journal of the American Medical Association, Vol. 313, No. 7, 2015, p. 707-716.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction.

AU - Szummer, Karolina

AU - Oldgren, Jonas

AU - Lindhagen, Lars

AU - Carrero, Juan Jesus

AU - Evans, Marie

AU - Spaak, Jonas

AU - Edfors, Robert

AU - Jacobson, Stefan H

AU - Andell, Pontus

AU - Wallentin, Lars

AU - Jernberg, Tomas

PY - 2015

Y1 - 2015

N2 - Fondaparinux was associated with reduced major bleeding events and improved survival compared with low-molecular-weight heparin (LMWH) in a large randomized clinical trial involving patients with non-ST-segment elevation myocardial infarction (NSTEMI). Large-scale experience of the use of fondaparinux vs LMWH in a nontrial setting is lacking.

AB - Fondaparinux was associated with reduced major bleeding events and improved survival compared with low-molecular-weight heparin (LMWH) in a large randomized clinical trial involving patients with non-ST-segment elevation myocardial infarction (NSTEMI). Large-scale experience of the use of fondaparinux vs LMWH in a nontrial setting is lacking.

U2 - 10.1001/jama.2015.517

DO - 10.1001/jama.2015.517

M3 - Article

C2 - 25688782

SN - 1538-3598

VL - 313

SP - 707

EP - 716

JO - JAMA: The Journal of the American Medical Association

JF - JAMA: The Journal of the American Medical Association

IS - 7

ER -

Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction.

Abstract

Subject classification (UKÄ)

Access to Document

Fingerprint

Cite this